Pharma companies move towards systematic access planning approaches: 2021 Access to Medicine Index

Express Pharma's News Bureau quotes Jayasree Iyer on the "strategic shift" in access planning, but reports that many late-stage R&D projects and products already on the market are still not supported by access plans.

The article draws attention to Pfizer's rank among the top five leading pharmaceutical companies of the 2021 Index, partly due to its access planning approach. It also discusses the focus of the 20 companies' R&D pipelines which continue to target HIV/AIDS, tuberculosis and malaria in addition to the novel coronavirus.